AzTrials
AzTrials

Atrial FibrillationNCT00321204

A Retrospective Study of the Role of Thiazolidinediones to Reduce the Incidence of Atrial Arrhythmias

An observational study of Atrial Fibrillation, run by Emory University at 3 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

It is well known that abnormal heart beats from the top parts of the heart, atrial fibrillation (AF) and atrial flutter (Aflut), occur frequently after most types of cardiac surgeries. Postoperative AF and Aflut are associated with significant morbidity, longer hospital stay, and higher related costs. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Atrial Fibrillation
What is being tested?
TZD reducing the incidence of atrial arrhythmias
Type of treatment
Surgery or procedure
How many people
600 participants
Where
3 sitesUnited States
Study dates
Dec 2005to Feb 2007
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patient who underwent elective cardiac Surgery in the Emory University Hospital, Crawford Long Hospital, or the Va Medical Center between 2000-2005.-

Who cannot join

  • -

Trial locations and contacts

3 sites in 1 country.

United States3 sites
  • Emory University Hospital

    Atlanta, Georgia, 30322

  • Emory Crawford Long Hospital

    Atlanta, Georgia, 30365

  • Veteran Administration Medical Center

    Decatur, Georgia, 30033

Other trials in United States

About this study

Official title: A Retrospective Study of the Role of Thiazolidinediones to Reduce the Incidence of Atrial Arrhythmias in Patients After Cardiac Surgery

It is well known that abnormal heart beats from the top parts of the heart, atrial fibrillation (AF) and atrial flutter (Aflut), occur frequently after most types of cardiac surgeries. Postoperative AF and Aflut are associated with significant morbidity, longer hospital stay, and higher related costs. Currently therapies are marginally effective at preventing this abnormal heart beat. The incidence of abnormal heart beats after cardiac surgery seems to be a function of the amount of inflammation and oxidative stress induced. Our group and others have shown that atrial abnormal heart beats are associated with increased oxidative stress. Thiazolidinediones (TZDs) are medications used to treat diabetes. Beside their glucose lowering effects, TZDs are shown to exhibit anti-inflammatory and antioxidant properties. Therefore, we propose to retrospectively analyze the effect of pre-operative TZDs on the incidence of post-operative AF or Aflut. This study will involve retrospective chart reviews without further patient contact of all patients having undergone cardiac surgery in Emory University Hospital, Crawford Long Hospital, or the VA Medical Center from 2000 to 2005. This study is preparatory to a funding proposal for a prospective trial.

Read the detailed description

1.0 Background

Cardiac surgery is associated with many perioperative complications, including supraventricular arrhythmias.(1-4) Atrial fibrillation occurs in 15 to 40% of patients after coronary artery bypass grafting (CABG) and up to 60% after CABG and valve repair. It can lead to significant complications such as stroke, prolonged hospitalizations, increasing mortality and morbidity.(1;5)

Post-operative atrial arrhythmias seem to be related to the degree of inflammation and oxidative stress induced during surgery.(2-4) Our group and others have shown that atrial arrhythmias are associated with increased oxidative stress.(6-10) Moreover, increased oxidative stress associated with angiotensin II-mediated NADPH oxidase activation leads to electrical abnormalities likely to propagate arrhythmias.(11;12)

Thiazolidinediones (TZDs) are antidiabetic agents that enhance insulin sensitivity through activating peroxisome proliferators-activated receptor (PPAR) gamma. Beside their glucose lowering effects, TZDs are shown to exhibit anti-inflammatory and antioxidant properties.(13-17)

2.0 Objectives

Based on the discussion above, we hypothesize that pre-operative use of TZDs will decrease post-operative AF or Aflut incidence. This study will be a retrospective cohort analysis of all patients that underwent elective cardiac surgeries between 2000-2005 at Emory University Hospital, Crawford Long Hospital, or the Atlanta Veterans Affairs Medical Center to evaluate the relationship of pre-operative TZD use to the incidence of post-operative atrial arrhythmias.. This study is undertaken in preparation for a funding proposal for a prospective trial.

3.0 Patient Selection

3.1 Eligibility criteria:

  1. All patients that patients who underwent elective cardiac surgery in the Emory University Hospital, Crawford Long Hospital, or the VA Medical Center between 2000-2005.

3.2 Ineligibility criteria:

  1. Emergent operations.
  2. The presence of AF or Aflut at the time of surgery.
  3. Patients without adequate documentation of atrial rhythm following surgery.
  4. New York Heart Association (NYHA) class IV heart failure at the time of surgery.
  5. Hyperthyroidism
  6. Implanted devices for designed for active management of atrial arrhythmias by pacing or defibrillation
  7. Known illicit drug use
  8. Known ethanol abuse
  9. Electrophysiological ablation for atrial tachycardia within 6 months of the operation.

4.0 Registration and randomization: none

5.0 Therapy: none

6.0 Pathology: none

7.0 Patient assessment: none

8.0 Data collection: Data will be collected from review of the patient's hospital charts, from telemetry recordings, and ECGs to document the presence or absence of AF or Aflut during the hospital admission for cardiac surgery. The presence or absence of atrial fibrillation will be diagnosed on the basis of an electrocardiographic recording and confirmed by a cardiologist. Demographic data collected will include: age, race, sex, body mass index, blood pressure, NYHA classification, Killip classification, and the history of previous myocardial infarction, hypertension, diabetes, smoking, alcohol use, antiarrhythmic drug use, presence and type of pacemaker if any, history of AF or Aflut, previous cardioversions, type of operation, and length of operation. Patients enrolled in this study will be given unique study numbers. No follow up data will be required from patients.

9.0 Statistical considerations: This study design is a retrospective chart review of a cohort of patients undergoing cardiac surgery to determine if there is an association between pre-operative TZD use and the incidence of post-operative atrial fibrillation or Aflut. The null hypothesis is that there is no association between the preoperative use of TZDs and postoperative AF and Aflut. Within the cohort, those patients with AF or Aflut will be compared to those without these atrial arrhythmias in the post-operative period. Baseline data for the two groups will be expressed as mean ± standard deviation for continuous variables, and frequencies for categorical variables. Differences in baseline characteristics between the groups will be examined by use of Fisher exact and Mann-Whitney tests for categorical and continuous variables, respectively. Quantification of any association between pre-operative TZD and the presence of atrial fibrillation will modeled by logistical regression analysis after adjusting for other variables that may affect arrhythmia frequency.

Being tested
TZD reducing the incidence of atrial arrhythmias
Keywords
Atrial Fibrillation, Atrial Flutter, Cardiac Surgery, Thiazolidinediones
Medical subject headings
Atrial Fibrillation, Atrial Flutter

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TZD reducing the incidence of atrial arrhythmiasProcedure or surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 May 2006 (estimated)
  2. Study startDec 2005
  3. Primary completionFeb 2007
  4. Study completionFeb 2007

Why it stopped: Terminated: We are no longer recruiting.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Enrolment
600 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00321204
Sponsor's protocol ID
IRB00002175
Other IDs
1308-2005
Status last verified
Apr 2014
First submitted
1 May 2006
Last updated
23 Apr 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Atrial Fibrillation, run by Emory University at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 23 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Terminated: We are no longer recruiting.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in